SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
POZN Analysis & Videos »
POZN: Bull or Bear?
FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR
POZN
|
|
|
-26.76%
in
131 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
Buy-Rated Pozen Worth the Risks
POZN
-58.91%
in
548 days
We expect the second quarter 2008 will be positive with respect to EPS and cash-flow based on the $20 million Glaxo milestone on the approval of Treximet.
|
The FDA's approval of Treximet should lead to profitability in the second quarter.
POZN
|
|
|
-57.63%
in
569 days
Pozen and partner GlaxoSmithKline announced late this
evening that the U.S. Food and Drug Administration (FDA)
has approved Treximet for the acute treatment of migraine
attacks with or without aura in adults.
The news was as expected and results in a $20 million
milestone from Glaxo ($10 million for approval and $10
million for the launch) to be recorded by Pozen in the second
quarter of 2008. This should lead to profitability in the
second quarter.
We are maintaining our Buy rating and $18 near-term price
target on the shares. We are buyers on this positive ne...
|
People Bullish on POZN
People Bearish on POZN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on POZN |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Pozen Inc.
- Answers.com
